Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
An alkyl and phenyl technology, applied in the field of substituted guanidine derivatives, can solve the problems of undisclosed dementia, schizophrenia, cognitive impairment, etc.
Inactive Publication Date: 2010-01-13
ASTELLAS PHARMA INC
View PDF9 Cites 7 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, in these gazettes, there is no disclosure of uses for dementia, schizophrenia, cognitive impairment, etc.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
preparation example Construction
[0193] (Preparation of raw material compound)
[0194] The raw material compounds (1) to (4) in the above production methods can be produced, for example, by the following methods, known methods or modified methods thereof.
[0195] (Raw material synthesis 1)
[0196] [chemical 15]
[0197]
[0198] (In the formula, Q and U represent leaving groups respectively, and any one represents -Br, -Cl, -I or -O-SO 2 -CF 3 etc., the other side means -B(OH) 2 or B(O-lower alkyl) 2 Wait. R 10 Represents a protecting group for a carboxyl group such as a lower alkyl group or benzyl group. )
[0199] In the raw material compound (1), R 4 The compound that is H can be directly prepared by the above-mentioned reaction route, or by the -OR of the thus prepared compound (1a) 10 Prepared by converting to a leaving group.
[0200] Among them, the coupling reaction can be passed through "Synthetic Communications", (UK), 1981, Volume 11, p.513-519; "Synlett", (Germany), 2000, Volume 6...
Embodiment
[0220] Hereinafter, a method for producing a compound contained in formula (I), which is an active ingredient of the present invention, will be described as an example. In addition, the production method of the compound used as a raw material is demonstrated as a production example. The production method of compound (I) is not limited to the production methods shown in the specific examples below, and can also be produced by a combination of these production methods, known production methods or their improved methods.
[0221] In the description of the following preparation examples and the tables described later, the following abbreviations are used for the measured values by mass spectrometry.
[0224] By reacting methyl 3-nitro-4-{[(trifluoromethyl)sulfonyl]oxy}benzoate with phenylboronic acid, potassium phosphate, tetrakis(triphenylphosphine)palladium in DMF with heating , to obtain methyl 2-nitrobiphenyl-4-carboxylate. FAB+: 258.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
An object of the present invention is to provide a novel and excellent agent for treating or preventing dementia, schizophrenia and the like, based on the 5-HT 5A receptor modulating action. It was confirmed that a compound characterized by a structure that a tricyclic hetero ring having a pyrrole ring at the center and guanidine are bonded via a carbonyl group has a potent 5-HT 5A receptor modulating action and an excellent pharmacological action based thereon, and thus, it was found that the compound can be an excellent agent for treating or preventing dementia, schizophrenia, bipolar disorder, or attention deficit hyperactivity disorder, particularly for memory-related functional disorders such as cognitive impairments including dementia and schizophrenia, thereby completing the present invention.
Description
technical field [0001] The present invention relates to substituted guanidine derivatives having medicinal properties, especially 5-HT 5A It can be used as a pharmaceutical composition for the treatment or prevention of dementia, schizophrenia and the like due to its receptor regulating effect. Background technique [0002] Dementia is a syndrome based on decreased brain function, memory impairment, and judgment impairment caused by acquired brain disorders, and vascular dementia and Alzheimer's dementia are representative causative diseases. In the past, drugs for the treatment of these diseases have been studied, but the clinical needs could not be fully met. For example, it is reported that cholinesterase inhibitors such as Aricept, which are widely used as a therapeutic drug for Alzheimer's dementia, have insufficient effects (Curr.Neurol.Neurosci.rep., 5(6) , 455-457, 2005; Eur. J. Pharmacol., 346, 1-13, 1998). In addition, side effects produced by stimulation of the...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more